Zhiqiang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhiqiang Zhang has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Junji Xing
Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Academic Institute, Houston Methodist, Houston, USA
14 shared publications Ao Zhang
Department of Surgery and Immunobiology and Transplant Science Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, USA
7 shared publicationsLaurie J. Minze
Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Academic Institute, Houston Methodist, Houston, TX, 77030, USA
6 shared publications- Xian Chang Li
Immunobiology and Transplant Science Center and Department of Surgery, Houston Methodist Hospital, Texas Medical Center, Houston, TX
6 shared publications Mingli Fang
Department of Surgery and Immunobiology and Transplant Science Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, USA
5 shared publicationsYong Du
Department of Surgery and Immunobiology and Transplant Science Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, USA
5 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (9) , 2825-2843
Antiviral innate immunity in myocarditis: mechanisms and emerging therapeutics
Antiviral innate immunity is a decisive determinant of whether cardiotropic viral infection resolves or progresses to myocarditis and deadly heart failure. Viral myocarditis (VM) remains a leading cause of sudden death in children and young adults, yet its human pathophysiological mechanisms remain incompletely understood and effective therapies are limited. In this Review, we map the cellular and molecular logic of cardiac antiviral innate immunity from first sensing to therapeutic opportunity and synthesize how these responses set the myocardial ‘inflammatory set point’ across cardiac-resident cells and recruited innate immune cells. We highlight RNA- and DNA-sensing immune signaling pathways that detect cardiotropic RNA and DNA viruses to collectively shape viral control and heart injury during VM. Finally, we connect mechanisms to translation by summarizing emerging biomarkers and clinical trials and by proposing a phase- and etiology-guided therapeutic framework that pairs antiviral immunomodulation with timely restraint of innate proinflammatory amplifiers to limit heart damage and prevent progression from VM to heart failure. This review will provide a roadmap of antiviral innate immunity to accelerate mechanistic discovery and targeted therapy for VM and virus-associated cardiovascular diseases.
- 3 September 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (9) , 2825-2843
Open AccessAntiviral innate immunity in myocarditis: mechanisms and emerging therapeutics
Antiviral innate immunity is a decisive determinant of whether cardiotropic viral infection resolves or progresses to myocarditis and deadly heart failure. Viral myocarditis (VM) remains a leading cause of sudden death in children and young adults, yet its human pathophysiological mechanisms remain incompletely understood and effective therapies are limited. In this Review, we map the cellular and molecular logic of cardiac antiviral innate immunity from first sensing to therapeutic opportunity and synthesize how these responses set the myocardial ‘inflammatory set point’ across cardiac-resident cells and recruited innate immune cells. We highlight RNA- and DNA-sensing immune signaling pathways that detect cardiotropic RNA and DNA viruses to collectively shape viral control and heart injury during VM. Finally, we connect mechanisms to translation by summarizing emerging biomarkers and clinical trials and by proposing a phase- and etiology-guided therapeutic framework that pairs antiviral immunomodulation with timely restraint of innate proinflammatory amplifiers to limit heart damage and prevent progression from VM to heart failure. This review will provide a roadmap of antiviral innate immunity to accelerate mechanistic discovery and targeted therapy for VM and virus-associated cardiovascular diseases.
- Open Access
- 15 July 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
TRIM47 catalyzes MAVS SUMOylation to safeguard chronic viral infections and tissue inflammation
Chronic tissue inflammation causes progressive tissue damage, organ dysfunction, and increased susceptibility to inflammatory diseases. Viral infections are major drivers of this process, but the molecular mechanisms linking antiviral immune responses to persistent inflammation and tissue pathology remain poorly understood. The function of TRIM47 was examined using primary macrophages and mouse models of RNA virus infection. Alveolar macrophages, peritoneal macrophages, and bone marrow-derived macrophages (BMDM) from wild-type and Trim47-deficient (Trim47-KO) mice were treated with RNA viruses or RNA mimics, and antiviral cytokine production was quantified. Sublethal reovirus and influenza A virus infection mouse models were used to evaluate survival, cytokine responses, and viral titers in vivo. Liquid chromatography-tandem mass spectrometry (LC-MS) was used to identify TRIM47-interacting proteins. Molecular and biochemical assays were used to examine post-translational modification, aggregation and activation of mitochondrial antiviral-signaling protein (MAVS). TRIM47 was highly expressed in macrophages, and TRIM47 deficiency in BMDM markedly reduced type I interferon (IFN-I) production following RNA virus infection or RNA mimics stimulation. In sublethal RNA virus infection mouse models, Trim47-KO mice exhibited reduced survival, impaired IFN-I responses, higher viral titers, increased inflammatory cell infiltration and tissue inflammation including myocarditis compared to wild-type mice. Mechanistically, TRIM47 interacted with MAVS and promoted SUMO1-mediated MAVS SUMOylation at K297 and K348, thereby enhancing MAVS aggregation and activation and driving robust IFN-I, IL-1β and IL-18 production in macrophages. These findings establish TRIM47 as a molecular switch of MAVS activation and antiviral cytokine responses in macrophages, highlighting its role in restricting RNA virus infection and mitigating inflammation. This study provides mechanistic insight into host pathways that may be therapeutically leveraged in chronic viral inflammation.
- 15 July 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessTRIM47 catalyzes MAVS SUMOylation to safeguard chronic viral infections and tissue inflammation
Chronic tissue inflammation causes progressive tissue damage, organ dysfunction, and increased susceptibility to inflammatory diseases. Viral infections are major drivers of this process, but the molecular mechanisms linking antiviral immune responses to persistent inflammation and tissue pathology remain poorly understood. The function of TRIM47 was examined using primary macrophages and mouse models of RNA virus infection. Alveolar macrophages, peritoneal macrophages, and bone marrow-derived macrophages (BMDM) from wild-type and Trim47-deficient (Trim47-KO) mice were treated with RNA viruses or RNA mimics, and antiviral cytokine production was quantified. Sublethal reovirus and influenza A virus infection mouse models were used to evaluate survival, cytokine responses, and viral titers in vivo. Liquid chromatography-tandem mass spectrometry (LC-MS) was used to identify TRIM47-interacting proteins. Molecular and biochemical assays were used to examine post-translational modification, aggregation and activation of mitochondrial antiviral-signaling protein (MAVS). TRIM47 was highly expressed in macrophages, and TRIM47 deficiency in BMDM markedly reduced type I interferon (IFN-I) production following RNA virus infection or RNA mimics stimulation. In sublethal RNA virus infection mouse models, Trim47-KO mice exhibited reduced survival, impaired IFN-I responses, higher viral titers, increased inflammatory cell infiltration and tissue inflammation including myocarditis compared to wild-type mice. Mechanistically, TRIM47 interacted with MAVS and promoted SUMO1-mediated MAVS SUMOylation at K297 and K348, thereby enhancing MAVS aggregation and activation and driving robust IFN-I, IL-1β and IL-18 production in macrophages. These findings establish TRIM47 as a molecular switch of MAVS activation and antiviral cytokine responses in macrophages, highlighting its role in restricting RNA virus infection and mitigating inflammation. This study provides mechanistic insight into host pathways that may be therapeutically leveraged in chronic viral inflammation.
- Top Cited PapersOpen Access
- 12 August 2025
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-22
Therapeutic landscape of ovarian cancer: recent advances and emerging therapies
Ovarian cancer ranks as the seventh most common malignancy and the eighth leading cause of cancer-related death in women worldwide. Most patients are diagnosed at an advanced stage, resulting in poor survival outcomes. The standard treatment is primary debulking surgery (PDS) with platinum-based chemotherapy, however interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) is an alternative for select cases. In this review, we summarize recent advancements in the therapeutic landscape of ovarian cancer, focusing on targeted therapies, immunotherapy, and novel drug delivery systems. Poly (ADP-ribose) polymerase (PARP) inhibitors have markedly improved progression-free survival in BRCA-mutated and homologous recombination deficiency (HRD)-positive patients. Antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), chimeric antigen receptor T (CAR-T) cell therapy, and tumor vaccines are emerging strategies, but they face challenges due to treatment resistance and tumor microenvironment suppression. Future research should focus on combination therapies, ADCs optimization, and immunotherapy refinement, while also integrating nanotechnology and 3D organoid models to enhance treatment precision to improve survival outcomes and quality of life for ovarian cancer patients.
- 12 August 2025
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-22
Top Cited PapersOpen AccessTherapeutic landscape of ovarian cancer: recent advances and emerging therapies
Ovarian cancer ranks as the seventh most common malignancy and the eighth leading cause of cancer-related death in women worldwide. Most patients are diagnosed at an advanced stage, resulting in poor survival outcomes. The standard treatment is primary debulking surgery (PDS) with platinum-based chemotherapy, however interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) is an alternative for select cases. In this review, we summarize recent advancements in the therapeutic landscape of ovarian cancer, focusing on targeted therapies, immunotherapy, and novel drug delivery systems. Poly (ADP-ribose) polymerase (PARP) inhibitors have markedly improved progression-free survival in BRCA-mutated and homologous recombination deficiency (HRD)-positive patients. Antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), chimeric antigen receptor T (CAR-T) cell therapy, and tumor vaccines are emerging strategies, but they face challenges due to treatment resistance and tumor microenvironment suppression. Future research should focus on combination therapies, ADCs optimization, and immunotherapy refinement, while also integrating nanotechnology and 3D organoid models to enhance treatment precision to improve survival outcomes and quality of life for ovarian cancer patients.
- Open Access
- 31 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Apex1 safeguards genomic stability to ensure a cytopathic T cell fate in autoimmune disease models
T cells have a remarkable capacity to clonally expand, a process that is intricately linked to their effector activities. As vigorously proliferating T cell also incur substantial DNA lesions, how the dividing T cells safeguard their genomic integrity to allow the generation of T effector cells remains largely unknown. Here we report the identification of the apurinic/apyrimidinic endonuclease-1 (Apex1) as an indispensable molecule for the induction of cytopathic T effectors in mouse models. We demonstrate that conditional deletion of Apex1 in T cells resulted in a remarkable accumulation of baseless DNA sites in the genome of proliferating T cells, which further led to genomic instability and apoptotic cell death. Consequently, Apex1- deleted T cells failed to acquire any effector features after activation and failed to mediate autoimmune diseases and allergic tissue damages. Detailed mutational analyses pinpointed the importance of its endonuclease domain in the generation of T effector cells. We provide further evidence that inhibiting the base repair activities of Apex1 with chemical inhibitors similarly abrogated the induction of autoimmune diseases. Collectively, our study suggests that Apex1 serves as a gatekeeper for the generation of cytopathic T cells and that therapeutically targeting Apex1 may have important clinical implications in the treatment of autoimmune diseases.
- 31 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Open AccessApex1 safeguards genomic stability to ensure a cytopathic T cell fate in autoimmune disease models
T cells have a remarkable capacity to clonally expand, a process that is intricately linked to their effector activities. As vigorously proliferating T cell also incur substantial DNA lesions, how the dividing T cells safeguard their genomic integrity to allow the generation of T effector cells remains largely unknown. Here we report the identification of the apurinic/apyrimidinic endonuclease-1 (Apex1) as an indispensable molecule for the induction of cytopathic T effectors in mouse models. We demonstrate that conditional deletion of Apex1 in T cells resulted in a remarkable accumulation of baseless DNA sites in the genome of proliferating T cells, which further led to genomic instability and apoptotic cell death. Consequently, Apex1- deleted T cells failed to acquire any effector features after activation and failed to mediate autoimmune diseases and allergic tissue damages. Detailed mutational analyses pinpointed the importance of its endonuclease domain in the generation of T effector cells. We provide further evidence that inhibiting the base repair activities of Apex1 with chemical inhibitors similarly abrogated the induction of autoimmune diseases. Collectively, our study suggests that Apex1 serves as a gatekeeper for the generation of cytopathic T cells and that therapeutically targeting Apex1 may have important clinical implications in the treatment of autoimmune diseases.
- Open Access
- 11 October 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 18 (1) , 135-150
TRIM29 controls enteric RNA virus-induced intestinal inflammation by targeting NLRP6 and NLRP9b signaling pathways
- 11 October 2024
- Published by Elsevier in Mucosal Immunology
- Vol. 18 (1) , 135-150
Open AccessTRIM29 controls enteric RNA virus-induced intestinal inflammation by targeting NLRP6 and NLRP9b signaling pathways
- Open Access
- 12 November 2022
- Published by Elsevier in Aquaculture Reports
- Vol. 27, 101405
Molecular characterization of a novel C-type lectin receptors (CD302) in Nile tilapia (Oreochromis niloticus) and its functional analysis in host defense against bacterial infection
- 12 November 2022
- Published by Elsevier in Aquaculture Reports
- Vol. 27, 101405
Open AccessMolecular characterization of a novel C-type lectin receptors (CD302) in Nile tilapia (Oreochromis niloticus) and its functional analysis in host defense against bacterial infection
- Open Access
- 31 July 2022
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 29 (1) , 1-20
TRIM18 is a critical regulator of viral myocarditis and organ inflammation
Background: Infections by viruses including severe acute respiratory syndrome coronavirus 2 could cause organ inflammations such as myocarditis, pneumonia and encephalitis. Innate immunity to viral nucleic acids mediates antiviral immunity as well as inflammatory organ injury. However, the innate immune mechanisms that control viral induced organ inflammations are unclear. Methods: To understand the role of the E3 ligase TRIM18 in controlling viral myocarditis and organ inflammation, wild-type and Trim18 knockout mice were infected with coxsackievirus B3 for inducing viral myocarditis, influenza A virus PR8 strain and human adenovirus for inducing viral pneumonia, and herpes simplex virus type I for inducing herpes simplex encephalitis. Mice survivals were monitored, and heart, lung and brain were harvested for histology and immunohistochemistry analysis. Real-time PCR, co-immunoprecipitation, immunoblot, enzyme-linked immunosorbent assay, luciferase assay, flow cytometry, over-expression and knockdown techniques were used to understand the molecular mechanisms of TRIM18 in regulating type I interferon (IFN) production after virus infection in this study. Results: We find that knockdown or deletion of TRIM18 in human or mouse macrophages enhances production of type I IFN in response to double strand (ds) RNA and dsDNA or RNA and DNA virus infection. Importantly, deletion of TRIM18 protects mice from viral myocarditis, viral pneumonia, and herpes simplex encephalitis due to enhanced type I IFN production in vivo. Mechanistically, we show that TRIM18 recruits protein phosphatase 1A (PPM1A) to dephosphorylate TANK binding kinase 1 (TBK1), which inactivates TBK1 to block TBK1 from interacting with its upstream adaptors, mitochondrial antiviral signaling (MAVS) and stimulator of interferon genes (STING), thereby dampening antiviral signaling during viral infections. Moreover, TRIM18 stabilizes PPM1A by inducing K63-linked ubiquitination of PPM1A. Conclusions: Our results indicate that TRIM18 serves as a negative regulator of viral myocarditis, lung inflammation and brain damage by downregulating innate immune activation induced by both RNA and DNA viruses. Our data reveal that TRIM18 is a critical regulator of innate immunity in viral induced diseases, thereby identifying a potential therapeutic target for treatment.
- 31 July 2022
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 29 (1) , 1-20
Open AccessTRIM18 is a critical regulator of viral myocarditis and organ inflammation
Background: Infections by viruses including severe acute respiratory syndrome coronavirus 2 could cause organ inflammations such as myocarditis, pneumonia and encephalitis. Innate immunity to viral nucleic acids mediates antiviral immunity as well as inflammatory organ injury. However, the innate immune mechanisms that control viral induced organ inflammations are unclear. Methods: To understand the role of the E3 ligase TRIM18 in controlling viral myocarditis and organ inflammation, wild-type and Trim18 knockout mice were infected with coxsackievirus B3 for inducing viral myocarditis, influenza A virus PR8 strain and human adenovirus for inducing viral pneumonia, and herpes simplex virus type I for inducing herpes simplex encephalitis. Mice survivals were monitored, and heart, lung and brain were harvested for histology and immunohistochemistry analysis. Real-time PCR, co-immunoprecipitation, immunoblot, enzyme-linked immunosorbent assay, luciferase assay, flow cytometry, over-expression and knockdown techniques were used to understand the molecular mechanisms of TRIM18 in regulating type I interferon (IFN) production after virus infection in this study. Results: We find that knockdown or deletion of TRIM18 in human or mouse macrophages enhances production of type I IFN in response to double strand (ds) RNA and dsDNA or RNA and DNA virus infection. Importantly, deletion of TRIM18 protects mice from viral myocarditis, viral pneumonia, and herpes simplex encephalitis due to enhanced type I IFN production in vivo. Mechanistically, we show that TRIM18 recruits protein phosphatase 1A (PPM1A) to dephosphorylate TANK binding kinase 1 (TBK1), which inactivates TBK1 to block TBK1 from interacting with its upstream adaptors, mitochondrial antiviral signaling (MAVS) and stimulator of interferon genes (STING), thereby dampening antiviral signaling during viral infections. Moreover, TRIM18 stabilizes PPM1A by inducing K63-linked ubiquitination of PPM1A. Conclusions: Our results indicate that TRIM18 serves as a negative regulator of viral myocarditis, lung inflammation and brain damage by downregulating innate immune activation induced by both RNA and DNA viruses. Our data reveal that TRIM18 is a critical regulator of innate immunity in viral induced diseases, thereby identifying a potential therapeutic target for treatment.
- 23 May 2022
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (6) , 1-11
Mechanisms involved in controlling RNA virus-induced intestinal inflammation
Gastroenteritis is inflammation of the lining of stomach and intestines and causes significant morbidity and mortality worldwide. Many viruses, especially RNA viruses are the most common cause of enteritis. Innate immunity is the first line of host defense against enteric RNA viruses and virus-induced intestinal inflammation. The first layer of defense against enteric RNA viruses in the intestinal tract is intestinal epithelial cells (IECs), dendritic cells and macrophages under the intestinal epithelium. These innate immune cells express pathogen-recognition receptors (PRRs) for recognizing enteric RNA viruses through sensing viral pathogen-associated molecular patterns (PAMPs). As a result of this recognition type I interferon (IFN), type III IFN and inflammasome activation occurs, which function cooperatively to clear infection and reduce viral-induced intestinal inflammation. In this review, we summarize recent findings about mechanisms involved in enteric RNA virus-induced intestinal inflammation. We will provide an overview of the enteric RNA viruses, their RNA sensing mechanisms by host PRRs, and signaling pathways triggered by host PRRs, which shape the intestinal immune response to maintain intestinal homeostasis.
- 23 May 2022
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (6) , 1-11
Mechanisms involved in controlling RNA virus-induced intestinal inflammation
Gastroenteritis is inflammation of the lining of stomach and intestines and causes significant morbidity and mortality worldwide. Many viruses, especially RNA viruses are the most common cause of enteritis. Innate immunity is the first line of host defense against enteric RNA viruses and virus-induced intestinal inflammation. The first layer of defense against enteric RNA viruses in the intestinal tract is intestinal epithelial cells (IECs), dendritic cells and macrophages under the intestinal epithelium. These innate immune cells express pathogen-recognition receptors (PRRs) for recognizing enteric RNA viruses through sensing viral pathogen-associated molecular patterns (PAMPs). As a result of this recognition type I interferon (IFN), type III IFN and inflammasome activation occurs, which function cooperatively to clear infection and reduce viral-induced intestinal inflammation. In this review, we summarize recent findings about mechanisms involved in enteric RNA virus-induced intestinal inflammation. We will provide an overview of the enteric RNA viruses, their RNA sensing mechanisms by host PRRs, and signaling pathways triggered by host PRRs, which shape the intestinal immune response to maintain intestinal homeostasis.
- 23 March 2022
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 19 (6) , 687-701
The RNA helicase DHX15 is a critical regulator of natural killer-cell homeostasis and functions
The RNA helicase DHX15 is widely expressed in immune cells and traditionally thought to be an RNA splicing factor or a viral RNA sensor. However, the role of DHX15 in NK-cell activities has not been studied thus far. Here, we generated Dhx15-floxed mice and found that conditional deletion of Dhx15 in NK cells (Ncr1CreDhx15fl/fl mice) resulted in a marked reduction in NK cells in the periphery and that the remaining Dhx15-deleted NK cells failed to acquire a mature phenotype. As a result, Dhx15-deleted NK cells exhibited profound defects in their cytolytic functions. We also found that deletion of Dhx15 in NK cells abrogated their responsiveness to IL-15, which was associated with inhibition of IL-2/IL-15Rβ (CD122) expression and IL-15R signaling. The defects in Dhx15-deleted NK cells were rescued by ectopic expression of a constitutively active form of STAT5. Mechanistically, DHX15 did not affect CD122 mRNA splicing and stability in NK cells but instead facilitated the surface expression of CD122, likely through interaction with its 3′UTR, which was dependent on the ATPase domain of DHX15 rather than its splicing domain. Collectively, our data identify a key role for DHX15 in regulating NK-cell activities and provide novel mechanistic insights into how DHX15 regulates the IL-15 signaling pathway in NK cells.
- 23 March 2022
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 19 (6) , 687-701
The RNA helicase DHX15 is a critical regulator of natural killer-cell homeostasis and functions
The RNA helicase DHX15 is widely expressed in immune cells and traditionally thought to be an RNA splicing factor or a viral RNA sensor. However, the role of DHX15 in NK-cell activities has not been studied thus far. Here, we generated Dhx15-floxed mice and found that conditional deletion of Dhx15 in NK cells (Ncr1CreDhx15fl/fl mice) resulted in a marked reduction in NK cells in the periphery and that the remaining Dhx15-deleted NK cells failed to acquire a mature phenotype. As a result, Dhx15-deleted NK cells exhibited profound defects in their cytolytic functions. We also found that deletion of Dhx15 in NK cells abrogated their responsiveness to IL-15, which was associated with inhibition of IL-2/IL-15Rβ (CD122) expression and IL-15R signaling. The defects in Dhx15-deleted NK cells were rescued by ectopic expression of a constitutively active form of STAT5. Mechanistically, DHX15 did not affect CD122 mRNA splicing and stability in NK cells but instead facilitated the surface expression of CD122, likely through interaction with its 3′UTR, which was dependent on the ATPase domain of DHX15 rather than its splicing domain. Collectively, our data identify a key role for DHX15 in regulating NK-cell activities and provide novel mechanistic insights into how DHX15 regulates the IL-15 signaling pathway in NK cells.
- Open Access
- 1 June 2021
- Published by Elsevier in Cell Reports
- Vol. 35 (12) , 109205
DHX15 is required to control RNA virus-induced intestinal inflammation
- 1 June 2021
- Published by Elsevier in Cell Reports
- Vol. 35 (12) , 109205
Open AccessDHX15 is required to control RNA virus-induced intestinal inflammation